Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir

Correction Monini, P.; Sgadari, C.; Grosso, M. G.; Bellino, S.; Di Biagio, A.; Toschi, E.; Bacigalupo, I.; Sabbatucci, M.; Cencioni, G.; Salvi, E.; Leone, P.; Ensoli, B.; Barillari, G.; Moracci, G.; Carratelli, L.; Gatti, G.; Brambilla, L.; Brambati, M.; Ferrucci, S.; De Pita, O.; Pilla, M. A.; Di Carlo, A.; Giuliani, M.; Cottoni, F.; Cuccuru, M. A.; Calvieri, S.; Clerico, R.; Potenza, C.; Tirelli, U.; Simonelli, C.; Martellotta, F.; Strumia, R.; Borghi, A.; Del Giacco, S.; Moi, L.; Piludu, G.; Sirianni, M. C.; Campagna, M.; Sarmati, L.; Andreoni, M.; Bianchini, G.; Sheldon, J.; Milzer, J.; Schulz, T.

doi:10.1097/QAD.0b013e3283262a8d

HIV protease inhibitors have been shown to exert antiangiogenic and antitumor actions independently from their antiretroviral effect. Based on these studies, HIV-seronegative patients with classic Kaposi's sarcoma were treated with indinavir and followed for clinical evolution, drug pharmacokinetics and Kaposi's sarcoma biomarkers. A favorable clinical course was associated with high drug plasma levels, reduced production of basic fibroblast growth factor, lower numbers of circulating endothelial cells, and a decrease in antibody titers against human herpesvirus 8.

Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir

Correction Monini P.;Sgadari C.;Grosso M. G.;Bellino S.;Di Biagio A.;Toschi E.;Bacigalupo I.;Sabbatucci M.;Cencioni G.;Salvi E.;Leone P.;Ensoli B.;Barillari G.;Moracci G.;Carratelli L.;Gatti G.;Brambilla L.;Brambati M.;Ferrucci S.;De Pita O.;Pilla M. A.;Di Carlo A.;Giuliani M.;Cottoni F.;Cuccuru M. A.;Calvieri S.;Clerico R.;Potenza C.;Tirelli U.;Simonelli C.;Martellotta F.;Strumia R.;Borghi A.;Del Giacco S.;Moi L.;Piludu G.;Sirianni M. C.;Campagna M.;Sarmati L.;Andreoni M.;Bianchini G.;Sheldon J.;Milzer J.;Schulz T.

2009-01-01

Abstract

HIV protease inhibitors have been shown to exert antiangiogenic and antitumor actions independently from their antiretroviral effect. Based on these studies, HIV-seronegative patients with classic Kaposi's sarcoma were treated with indinavir and followed for clinical evolution, drug pharmacokinetics and Kaposi's sarcoma biomarkers. A favorable clinical course was associated with high drug plasma levels, reduced production of basic fibroblast growth factor, lower numbers of circulating endothelial cells, and a decrease in antibody titers against human herpesvirus 8.